Track Nanobac Pharmaceuticals's operating income ($4.9M) with charts, peers, and YoY trends.
Get informed when a big investor buys or sells
+ FollowAs of Dec 31, 2007
Trailing 12 months ending Dec 31, 2007
As of the most recent data (December 2007), NNBP shows a operating income of $4.9M. That compares with $4.8M in the prior-year period — up 2.1% year over year. Scroll down for historical charts and peer comparison views.
Compared with the year-ago period, NNBP's operating income is now $4.9M (was $4.8M) — a 2.1% year-over-year increase. Pairing that YoY change with peer averages gives a clearer picture of whether Nanobac Pharmaceuticals is outperforming or lagging.
Tracking NNBP's operating income over time shows whether Nanobac Pharmaceuticals is scaling, shrinking, or reshaping that part of the business. The current reading is $4.9M That compares with $4.8M in the prior-year period — up 2.1% year over year. Multi-quarter patterns matter more than any single print, which is why this page emphasizes history and peer comparison charts.
Besides this operating income page, Stockcircle has Nanobac Pharmaceuticals's full stock overview, other financial metrics, insider and congress trade tabs, and tools to follow the stock. Together they help you connect operating income (currently $4.9M) with ownership activity and broader fundamentals.
Nanobac Pharmaceuticals's operating income is $4.9M; compare it with other Healthcare names on the peer chart. Typical ranges vary by sub-industry, so always sanity-check against the closest competitors, not just the whole sector bucket.